Camp4 Therapeutics Corp (CAMP) Stock Price, Quote & News

Company Profile

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation i...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 651 8867

Website: www.camp4tx.com

Address:

One Kendall Square, 3rd Floor Building 1400 West, Cambridge, United States

STACKD0E Aug. 19 at 4:44 PM

$CAMP $TH $BKR $ARLP 🙃✨️

0 · Reply

ShangVXO Aug. 18 at 2:42 PM

$CAMP i’d definitely be annoyed if this ripped without me

0 · Reply

Slingshot Aug. 17 at 12:13 AM

$CAMP ⛺️☝️

0 · Reply

NewNewOld Aug. 16 at 9:33 PM

$CAMP looks interesting this 15 dollar price target. I would buy but I never buy this sector

0 · Reply

topstockalerts Aug. 14 at 11:58 PM

$CAMP this chart has gone from background noise to center stage.

0 · Reply

typhoonfish Aug. 14 at 7:04 PM

$CAMP what is the resistance on this thing it’s been stuck at 4:50 for months

0 · Reply

anachartanalyst Aug. 14 at 7:02 PM

$CAMP https://anachart.com/wp-content/uploads/2026/08/1786734127_soc-img.jpg

0 · Reply

kaedric_metrics Aug. 14 at 3:29 PM

$CAMP ✅ EPS: -$0.22 vs. -$0.24 expected — 8.3% beat ✅ Revenue: $1.78M vs. ~$1.35M expected — 31.8% beat ✅ Revenue up ~19% YoY ✅ Loss improved dramatically from -$0.62/share last year to -$0.22 For an early-stage biotech, I care about execution, cash runway and pipeline progress — and this quarter showed meaningful improvement on the financial side. With the recent CAMP4 catalysts and better-than-expected earnings, I’m increasingly bullish here. $5+ doesn’t look crazy to me if momentum continues. 🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀

0 · Reply

kaedric_metrics Aug. 12 at 5:35 PM

$CAMP Heeeerrrre weeeeee gooooooooo!!!!!

0 · Reply

TigrePeidando Aug. 12 at 11:52 AM

$CAMP Upward movement!!

0 · Reply

Camp4 Therapeutics reports Q2 EPS (58c), consensus (21c)

2026-08-16T13:27:37.000Z - 4 days ago

Camp4 Therapeutics price target raised to $15 from $12 at Piper Sandler

Aug 13, 2026, 4:05 PM EDT - 6 days ago

CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights

Aug 13, 2026, 7:00 AM EDT - 7 days ago

Camp4 Therapeutics Quarterly report: Q2 2026

Aug 13, 2026, 7:00 AM EDT - 7 days ago

Camp4 Therapeutics Earnings release: Q2 2026

Aug 6, 2026, 2:52 PM EDT - 13 days ago

CAMP4 advances rare disease treatment for SYNGAP1 into human trials

Aug 6, 2026, 8:00 AM EDT - 14 days ago

Camp4 Therapeutics Registration statement: Registration filing

Aug 4, 2026, 7:00 AM EDT - 16 days ago

CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement

2026-07-27T11:10:24.000Z - 24 days ago

Camp4 Therapeutics receives Australia TGA clearance for CMP-002 trial

Jul 27, 2026, 7:00 AM EDT - 24 days ago

CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder

Jul 17, 2026, 4:05 PM EDT - 4 weeks ago

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

2026-07-01T11:20:53.000Z - 7 weeks ago

X4 Pharmaceuticals appoints CAMP4 Therapeutics CFO Kelly Gold to board

XFOR

Jun 19, 2026, 4:05 PM EDT - 2 months ago

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-06-16T09:40:29.000Z - 2 months ago

Camp4 Therapeutics upgraded to Overweight from Neutral at JPMorgan

Jun 10, 2026, 11:00 AM EDT - 2 months ago

Camp4 Therapeutics Transcript: AGM 2026

2026-06-10T08:20:08.000Z - 2 months ago

Camp4 Therapeutics initiated with a Buy at Chardan

Jun 8, 2026, 6:30 AM EDT - 2 months ago

New Analysis Strengthens Mercator Gold System and Confirms High-Grade BIF Continuity

May 14, 2026, 7:00 AM EDT - 3 months ago

CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder

2026-05-07T22:28:59.000Z - 3 months ago

Camp4 Therapeutics reports Q1 EPS (32c), consensus (21c)

May 7, 2026, 4:05 PM EDT - 3 months ago

CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights

May 7, 2026, 7:00 AM EDT - 3 months ago

Camp4 Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

Camp4 Therapeutics Earnings release: Q1 2026

Apr 28, 2026, 8:00 AM EDT - 4 months ago

CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Camp4 Therapeutics Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Camp4 Therapeutics Proxy statement: Proxy filing

2026-04-14T10:54:06.000Z - 4 months ago

Camp4 Therapeutics initiated with a Buy at Rodman & Renshaw

Apr 13, 2026, 12:45 PM EDT - 4 months ago

Camp4 Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

2026-04-02T10:11:49.000Z - 5 months ago

Camp4 Therapeutics price target raised to $9 from $8 at Leerink

Mar 24, 2026, 7:00 AM EDT - 5 months ago

CAMP4 Appoints Michael MacLean to its Board of Directors

Mar 17, 2026, 10:00 AM EDT - 5 months ago

Camp4 Therapeutics Transcript: Stifel 2026 Virtual CNS Forum

2026-03-12T16:00:19.000Z - 5 months ago

Biotech Alert: Searches spiking for these stocks today

SPRB

2026-03-11T16:25:40.000Z - 5 months ago

Biotech Alert: Searches spiking for these stocks today

Mar 9, 2026, 8:40 AM EDT - 5 months ago

Camp4 Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 6, 2026, 4:05 PM EST - 5 months ago

CAMP4 to Participate in Upcoming Investor Conferences

Mar 5, 2026, 4:05 PM EST - 5 months ago

CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights

Mar 5, 2026, 7:00 AM EST - 6 months ago

Camp4 Therapeutics Annual report: Q4 2025

Mar 5, 2026, 6:00 AM EST - 6 months ago

Camp4 Therapeutics Slides: Corporate presentation

2026-02-19T15:50:18.000Z - 6 months ago

Camp4 Therapeutics participates in a conf call hosted by Cantor Fitzgerald

Jan 14, 2026, 6:45 PM EST - 7 months ago

Camp4 Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 9, 2026, 7:00 AM EST - 7 months ago

Camp4 Therapeutics Slides: Corporate presentation

Jan 6, 2026, 8:00 AM EST - 8 months ago

CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference

2025-12-18T12:21:08.000Z - 8 months ago

Camp4 Therapeutics prices 5M shares at $6.00 in underwritten public offering

2025-12-18T12:16:54.000Z - 8 months ago

Camp4 Therapeutics 5M share Secondary priced at $6.00

2025-12-18T12:11:53.000Z - 8 months ago

Camp4 Therapeutics, GSK enter strategic collaboration

GSK

Dec 18, 2025, 7:10 AM EST - 8 months ago

CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock

Dec 18, 2025, 7:00 AM EST - 8 months ago

CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries

2025-12-12T16:05:39.000Z - 8 months ago

Biotech Alert: Searches spiking for these stocks today

2025-12-11T16:45:34.000Z - 8 months ago

Biotech Alert: Searches spiking for these stocks today

IBIO

Dec 3, 2025, 4:00 PM EST - 9 months ago

Camp4 Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 10, 2025, 7:00 AM EST - 10 months ago

Camp4 Therapeutics Registration statement: Registration filing

Nov 6, 2025, 4:05 PM EST - 10 months ago

CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights

Nov 5, 2025, 6:00 PM EST - 10 months ago

Camp4 Therapeutics Quarterly report: Q3 2025

Nov 5, 2025, 6:00 PM EST - 10 months ago

Camp4 Therapeutics Earnings release: Q3 2025

Nov 3, 2025, 7:00 AM EST - 10 months ago

Camp4 Therapeutics Registration statement: Registration filing

Oct 21, 2025, 12:00 PM EDT - 10 months ago

Camp4 Therapeutics Transcript: Chardan's 9th Annual Genetic Medicines Conference

2025-10-02T10:46:18.000Z - 11 months ago

Camp4 Therapeutics initiated with an Overweight at Cantor Fitzgerald

2025-10-02T10:40:11.000Z - 11 months ago

Camp4 Therapeutics initiated with an Overweight at Cantor Fitzgerald

2025-10-01T12:10:16.000Z - 11 months ago

Camp4 Therapeutics initiates GLP toxicology studies for CMP-SYNGAP-01

Oct 1, 2025, 8:00 AM EDT - 11 months ago

CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01

Sep 10, 2025, 7:00 AM EDT - 1 year ago

CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders

Aug 14, 2025, 4:05 PM EDT - 1 year ago

CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights

Aug 13, 2025, 6:00 PM EDT - 1 year ago

Camp4 Therapeutics Quarterly report: Q2 2025

Aug 13, 2025, 6:00 PM EDT - 1 year ago

Camp4 Therapeutics Earnings release: Q2 2025

May 16, 2025, 6:00 AM EDT - 1 year ago

CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting

May 13, 2025, 4:05 PM EDT - 1 year ago

CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

May 13, 2025, 12:00 AM EDT - 1 year ago

Camp4 Therapeutics Quarterly report: Q1 2025

May 13, 2025, 12:00 AM EDT - 1 year ago

Camp4 Therapeutics Earnings release: Q1 2025

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Camp4 Therapeutics Proxy statement: Proxy filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Camp4 Therapeutics Proxy statement: Proxy filing

Apr 28, 2025, 4:30 PM EDT - 1 year ago

CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

Mar 27, 2025, 4:05 PM EDT - 1 year ago

CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 26, 2025, 7:00 PM EDT - 1 year ago

Camp4 Therapeutics Earnings release: Q4 2024

Mar 26, 2025, 7:00 PM EDT - 1 year ago

Camp4 Therapeutics Annual report: Q4 2024

Mar 18, 2025, 8:00 AM EDT - 1 year ago

CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

Mar 13, 2025, 10:39 PM EDT - 1 year ago

CORRECTION - CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025

Mar 13, 2025, 2:58 PM EDT - 1 year ago

CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025

Mar 10, 2025, 4:20 PM EDT - 1 year ago

Camp4 Therapeutics Transcript: Leerink Global Healthcare Conference 2025

Feb 12, 2025, 10:00 AM EST - 1 year ago

Camp4 Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Jan 14, 2025, 6:45 PM EST - 1 year ago

Camp4 Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference

Jan 14, 2025, 6:45 PM EST - 1 year ago

Camp4 Therapeutics Slides: 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 4:05 PM EST - 1 year ago

CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones

Dec 5, 2024, 1:00 PM EST - 1 year ago

Camp4 Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 2, 2024, 8:00 AM EST - 1 year ago

CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 4:05 PM EST - 1 year ago

CAMP4 Reports Third Quarter 2024 Financial Results

Nov 21, 2024, 7:00 AM EST - 1 year ago

Camp4 Therapeutics Quarterly report: Q3 2024

Nov 21, 2024, 7:00 AM EST - 1 year ago

Camp4 Therapeutics Earnings release: Q3 2024

Oct 10, 2024, 7:07 PM EDT - 2 years ago

CAMP4 Announces Pricing of Initial Public Offering

STACKD0E Aug. 19 at 4:44 PM

$CAMP $TH $BKR $ARLP 🙃✨️

0 · Reply

ShangVXO Aug. 18 at 2:42 PM

$CAMP i’d definitely be annoyed if this ripped without me

0 · Reply

Slingshot Aug. 17 at 12:13 AM

$CAMP ⛺️☝️

0 · Reply

NewNewOld Aug. 16 at 9:33 PM

$CAMP looks interesting this 15 dollar price target. I would buy but I never buy this sector

0 · Reply

topstockalerts Aug. 14 at 11:58 PM

$CAMP this chart has gone from background noise to center stage.

0 · Reply

typhoonfish Aug. 14 at 7:04 PM

$CAMP what is the resistance on this thing it’s been stuck at 4:50 for months

0 · Reply

anachartanalyst Aug. 14 at 7:02 PM

$CAMP https://anachart.com/wp-content/uploads/2026/08/1786734127_soc-img.jpg

0 · Reply

kaedric_metrics Aug. 14 at 3:29 PM

0 · Reply

kaedric_metrics Aug. 12 at 5:35 PM

$CAMP Heeeerrrre weeeeee gooooooooo!!!!!

0 · Reply

TigrePeidando Aug. 12 at 11:52 AM

$CAMP Upward movement!!

0 · Reply

ZeroSUM_ Aug. 12 at 2:59 AM

$CAMP I'm feeling better about it

1 · Reply

TigrePeidando Aug. 6 at 8:24 PM

$CAMP Another amazing day!! Let's keep up the fantastic work. See you all at $6 🚀🚀🚀

0 · Reply

Revicta Aug. 6 at 12:58 AM

$CAMP BIG NEWS!!!!! Sign the deal $NVDA nooowwwwwww 🚀🚀🚀🚀🚀🚀🚀

0 · Reply

TigrePeidando Aug. 5 at 11:41 PM

$CAMP 🟢 Bullish filings: ✅ CEO: 6,551 shares ✅ CFO: 6,551 ✅ CMO: 6,551 ✅ Director: 16,378 ✅ 5AM Ventures: 3,179,558 pre-funded warrant shares Total: 3,215,589 shares / about $4.92M committed. No insider selling. Management and a major backer are increasing exposure they they know the integration of AI into its therapeutic medicine platform will cause the stock to go up 📈📈📈📈📈

0 · Reply

CEOBuysDisclosures Aug. 5 at 11:10 PM

$CAMP CEO purchased 6,551 shares at $1.65 for a total of $10,809. Mandel-Brehm Josh now owns 284,968 shares. https://ceo-buys.com

0 · Reply

5G_C Aug. 5 at 1:01 AM

$CAMP Let's also not forget the big picture here. News of major partnerships and future deals are coming.

0 · Reply

Lane0507 Aug. 4 at 11:28 PM

$CAMP -As of the first quarter of 2026, the company reported about $99.2 million in cash and stated this is expected to fund operations into 2028 and reducing near-term financing pressure...

0 · Reply

topstockalerts Aug. 3 at 11:19 PM

$CAMP this is actually holding up way better than I thought

0 · Reply

Revicta Aug. 3 at 4:00 PM

$CAMP what did I tell you all!!!!! Congrats to all the longs.

0 · Reply

Revicta Jul. 27 at 5:16 PM

$CAMP HERE WE GOOOOOOOOOOOOOOO 📈📈📈📈📈📈📈📈📈📈📈📈📈📈📈📈📈

0 · Reply

TigrePeidando Jul. 27 at 1:40 PM

$CAMP It's the kind of catalyst that can lead to a higher valuation because it: ✔️ Removes a major regulatory hurdle ✔️ Brings in significant funding ✔️ Moves the lead program into human trials 📈📈📈📈📈📈 🚀🚀🚀🚀🚀🚀🚀🚀

1 · Reply

5G_C Jul. 27 at 1:35 PM

$CAMP Earnings next month as well. Keep an eye on $CAMP

0 · Reply

Market Cap	307.49M
Revenue (ttm)	3.50M
Net Income (ttm)	-80.40M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,297.14%
Debt to Equity Ratio	0.00

Volume	228,500
Avg Vol	266,992
Day's Range	N/A - N/A
Shares Out	62.75M
Stochastic %K	29%
Beta	0.22
Analysts	Strong Sell
Price Target	$8.79